• DOI:10.1016/j.canlet.2010.05.015
Corpus ID: 8904706

Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells.

@article{Takizawa2010TrilostaneAI,
  title={Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells.},
  author={I. Takizawa and T. Nishiyama and N. Hara and T. Hoshii and F. Ishizaki and Y. Miyashiro and K. Takahashi},
  journal={Cancer letters},
  year={2010},
  volume={297 2},
  pages={
          226-30
        }
}

I. Takizawa, T. Nishiyama, +4 authors K. Takahashi

Published 2010

Chemistry, Medicine

Cancer letters

The intracellular androgen metabolism and cell activity in prostate cancer cells with mutated (LNCaP-FGC) or wild-type (VCaP) androgen receptors in the presence of trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, were examined. Trilostane suppressed the intracellular production of androstenedione, testosterone, and dihydrotestosterone from dehydroepiandrosterone in LNCaP-FGC cells. In both LNCaP-FGC and VCaP cell types, the prostate-specific antigen (PSA) levels in media were… CONTINUE READING

View on PubMed

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed